Glomerulonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major glomerulonephritis markets reached a value of US$ 748.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,105.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.61% during 2024-2034.
The glomerulonephritis market has been comprehensively analyzed in IMARC's new report titled "Glomerulonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Glomerulonephritis is a medical condition characterized by inflammation of the glomeruli, which are the tiny filters in the kidneys responsible for filtering waste and excess fluid from the blood. This disease can impair the normal functioning of the kidneys, leading to the buildup of toxins in the body. Individuals suffering from glomerulonephritis usually have no obvious signs of the illness. But in some cases, the most common indications include blood in the urine, which may make the urine look pink, brown, or red, fatigue, nausea, rashes, high blood pressure, shortness of breath, pain in the joints or abdomen, urinary inconsistency, swelling in the legs or face, etc. The diagnosis of this ailment typically involves several steps, such as a medical history, physical examination, imaging tests, blood workups, and a kidney biopsy. During the medical investigation, a healthcare practitioner will check for signs of kidney diseases, like high blood pressure and fluid retention. Additionally, blood workups and imaging studies are utilized to detect abnormalities and assess the structure and size of the kidneys.
The increasing incidences of diabetes and chronic high blood pressure that can damage the blood vessels and nephrons within the kidneys are primarily driving the glomerulonephritis market. In addition to this, the rising cases of autoimmune diseases, in which the immune system mistakenly attacks the body's own tissues, are also bolstering the market growth. Furthermore, the inflating utilization of effective medications, like angiotensin-converting enzyme (ACE) inhibitors, diuretics, antihypertensive agents, etc., to manage the underlying indications of the ailment is acting as another significant growth-inducing factor. Besides this, the escalating application of intravenous immunoglobulin therapy, owing to its numerous benefits over conventional treatments, such as regulating the immune system, preserving renal function, and decreasing inflammation in patients, is further creating a positive outlook for the market. Moreover, the widespread adoption of plasmapheresis techniques, which help to remove harmful autoantibodies from the bloodstream, thereby reducing the burden on the kidneys and slowing down the progression of glomerular damage, is expected to drive the glomerulonephritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the glomerulonephritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for glomerulonephritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the glomerulonephritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the glomerulonephritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the glomerulonephritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current glomerulonephritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the glomerulonephritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the glomerulonephritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the glomerulonephritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of glomerulonephritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of glomerulonephritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of glomerulonephritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with glomerulonephritis across the seven major markets?
What is the size of the glomerulonephritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of glomerulonephritis?
What will be the growth rate of patients across the seven major markets?
Glomerulonephritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for glomerulonephritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the glomerulonephritis market?
What are the key regulatory events related to the glomerulonephritis market?
What is the structure of clinical trial landscape by status related to the glomerulonephritis market?
What is the structure of clinical trial landscape by phase related to the glomerulonephritis market?
What is the structure of clinical trial landscape by route of administration related to the glomerulonephritis market?
The glomerulonephritis market has been comprehensively analyzed in IMARC's new report titled "Glomerulonephritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Glomerulonephritis is a medical condition characterized by inflammation of the glomeruli, which are the tiny filters in the kidneys responsible for filtering waste and excess fluid from the blood. This disease can impair the normal functioning of the kidneys, leading to the buildup of toxins in the body. Individuals suffering from glomerulonephritis usually have no obvious signs of the illness. But in some cases, the most common indications include blood in the urine, which may make the urine look pink, brown, or red, fatigue, nausea, rashes, high blood pressure, shortness of breath, pain in the joints or abdomen, urinary inconsistency, swelling in the legs or face, etc. The diagnosis of this ailment typically involves several steps, such as a medical history, physical examination, imaging tests, blood workups, and a kidney biopsy. During the medical investigation, a healthcare practitioner will check for signs of kidney diseases, like high blood pressure and fluid retention. Additionally, blood workups and imaging studies are utilized to detect abnormalities and assess the structure and size of the kidneys.
The increasing incidences of diabetes and chronic high blood pressure that can damage the blood vessels and nephrons within the kidneys are primarily driving the glomerulonephritis market. In addition to this, the rising cases of autoimmune diseases, in which the immune system mistakenly attacks the body's own tissues, are also bolstering the market growth. Furthermore, the inflating utilization of effective medications, like angiotensin-converting enzyme (ACE) inhibitors, diuretics, antihypertensive agents, etc., to manage the underlying indications of the ailment is acting as another significant growth-inducing factor. Besides this, the escalating application of intravenous immunoglobulin therapy, owing to its numerous benefits over conventional treatments, such as regulating the immune system, preserving renal function, and decreasing inflammation in patients, is further creating a positive outlook for the market. Moreover, the widespread adoption of plasmapheresis techniques, which help to remove harmful autoantibodies from the bloodstream, thereby reducing the burden on the kidneys and slowing down the progression of glomerular damage, is expected to drive the glomerulonephritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the glomerulonephritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for glomerulonephritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the glomerulonephritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the glomerulonephritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the glomerulonephritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current glomerulonephritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the glomerulonephritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the glomerulonephritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the glomerulonephritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of glomerulonephritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of glomerulonephritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of glomerulonephritis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with glomerulonephritis across the seven major markets?
What is the size of the glomerulonephritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of glomerulonephritis?
What will be the growth rate of patients across the seven major markets?
Glomerulonephritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for glomerulonephritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the glomerulonephritis market?
What are the key regulatory events related to the glomerulonephritis market?
What is the structure of clinical trial landscape by status related to the glomerulonephritis market?
What is the structure of clinical trial landscape by phase related to the glomerulonephritis market?
What is the structure of clinical trial landscape by route of administration related to the glomerulonephritis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GLOMERULONEPHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GLOMERULONEPHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GLOMERULONEPHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GLOMERULONEPHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GLOMERULONEPHRITIS - UNMET NEEDS
10 GLOMERULONEPHRITIS - KEY ENDPOINTS OF TREATMENT
11 GLOMERULONEPHRITIS - MARKETED PRODUCTS
11.1 List of Glomerulonephritis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 GLOMERULONEPHRITIS - PIPELINE DRUGS
12.1 List of Glomerulonephritis Pipeline Drugs Across the Top 7 Markets
12.1.1 LNP 023 - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MOR 202- HI-Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Efgartigimod - Argenx
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GLOMERULONEPHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GLOMERULONEPHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GLOMERULONEPHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Glomerulonephritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Glomerulonephritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Glomerulonephritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Glomerulonephritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Glomerulonephritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Glomerulonephritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Glomerulonephritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Glomerulonephritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Glomerulonephritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Glomerulonephritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Glomerulonephritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Glomerulonephritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Glomerulonephritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Glomerulonephritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Glomerulonephritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Glomerulonephritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Glomerulonephritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Glomerulonephritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Glomerulonephritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Glomerulonephritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Glomerulonephritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Glomerulonephritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Glomerulonephritis - Access and Reimbursement Overview
16 GLOMERULONEPHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GLOMERULONEPHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GLOMERULONEPHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 GLOMERULONEPHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 GLOMERULONEPHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 GLOMERULONEPHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 GLOMERULONEPHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 GLOMERULONEPHRITIS - UNMET NEEDS
10 GLOMERULONEPHRITIS - KEY ENDPOINTS OF TREATMENT
11 GLOMERULONEPHRITIS - MARKETED PRODUCTS
11.1 List of Glomerulonephritis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 GLOMERULONEPHRITIS - PIPELINE DRUGS
12.1 List of Glomerulonephritis Pipeline Drugs Across the Top 7 Markets
12.1.1 LNP 023 - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MOR 202- HI-Bio
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Efgartigimod - Argenx
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. GLOMERULONEPHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. GLOMERULONEPHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 GLOMERULONEPHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Glomerulonephritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Glomerulonephritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Glomerulonephritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Glomerulonephritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Glomerulonephritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Glomerulonephritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Glomerulonephritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Glomerulonephritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Glomerulonephritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Glomerulonephritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Glomerulonephritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Glomerulonephritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Glomerulonephritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Glomerulonephritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Glomerulonephritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Glomerulonephritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Glomerulonephritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Glomerulonephritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Glomerulonephritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Glomerulonephritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Glomerulonephritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Glomerulonephritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Glomerulonephritis - Access and Reimbursement Overview
16 GLOMERULONEPHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 GLOMERULONEPHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 GLOMERULONEPHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
